Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease?

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Calabrò, Luana ^a   Maio, Michele ^a  

^a UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

Anti CTLA4 antibody; Immunomodulating antibody; Mesothelioma; Therapy; Tremelimumab

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PLATINUM DERIVATIVE; TICILIMUMAB;

ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DISEASE ACTIVITY; DRUG ACTIVITY; HUMAN; IMMUNOMODULATION; LYMPHOCYTE COUNT; MALIGNANT MESOTHELIOMA; RADIODIAGNOSIS; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 84899128381     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27482     Document Type: Article

References (10)

1. Eggermont AM, Kroemer G, Zitvogel L. Immunotherapy and the concept of a clinical cure. Eur J Cancer 2013; 49:2965-7; PMID:23890942; http://dx.doi.org/10.1016/j.ejca.2013.06.019.
2. Calabrò L, Danielli R, Sigalotti L, Maio M. Clinical studies with anti-CTLA-4 antibodies in nonmelanoma indications. Semin Oncol 2010; 37:460-7; PMID:21074061; http://dx.doi.org/10.1053/j. seminoncol.2010.09.006.
3. Mullard A. New checkpoint inhibitors ride the immunotherapy tsunami. Nat Rev Drug Discov 2013; 12:489-92; PMID:23812256; http://dx.doi. org/10.1038/nrd4066.
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-44; PMID:12860938; http://dx.doi.org/10.1200/JCO.2003.11.136.
5. Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 2012; 75:360-7; PMID:21937142; http://dx.doi. org/10.1016/j.lungcan.2011.08.011.
6. Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol 2013; 14:1104-11; PMID:24035405; http://dx.doi.org/10.1016/S1470-2045(13)70381-4.
7. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009; 15:7412-20; PMID:19934295; http://dx.doi.org/10.1158/1078-0432.CCR-09-1624.
8. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15:257-60; PMID:14760119; http://dx.doi.org/10.1093/annonc/mdh059.
9. Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother 2013; 62:1021-8; PMID:23591982; http://dx.doi.org/10.1007/s00262-013-1418-6.
10. Calabrò L, Maio M. Biomarkers for immune checkpoint inhibitors. Lancet Oncol 2014; 15:e1; http://dx.doi.org/10.1016/S1470-2045(13)70573-4.